HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Says Industry Has Work Left To Do To Make Antiviral Claims For Topicals

This article was originally published in The Rose Sheet

Executive Summary

FDA has rejected a citizen petition seeking antiviral labeling for OTC products covered by the Healthcare Antiseptic Drug Products monograph

You may also be interested in...



Has COVID Changed US FDA’s Thinking About OTC Antiseptics?

The public health emergency has shown that the US needs more hand sanitizers on store shelves, not less, right?

Rep. Markey Calls For Triclosan Ban, Galvanized By Sympathetic FDA Letter

Rep. Ed Markey, D-Mass., wants many personal-care applications of triclosan banned and is crafting chemicals safety legislation after receiving letters from FDA and EPA acknowledging that there are concerns about the ingredient

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

UsernamePublicRestriction

Register

RS016865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel